To date, only three markers were approved by the United States Food and Drug Administration (FDA) [4], including microsatellite instability (MSI)/mismatch-repair deficiency (dMMR) [5], tumor mutation burden (TMB) [6] in pancancer, and PD-L1 expression in non-small cell lung cancer (NSCLC) [7]. This evidence concerns the gene CD274 and neoplasm.